user_input,retrieved_contexts,response,reference,faithfulness,answer_relevancy,context_precision
What is the title of the randomized trial conducted by Patchell RA and colleagues regarding the treatment of single metastases to the brain?,"['https://www.ncbi.nlm.nih.gov/pubmed/19960231. \n680. Mintz A, Perry J, Spithoff K, et al. Management of single brain \nmetastasis: a practice guideline. Curr Oncol 2007;14:131-143. Available \nat: https://www.ncbi.nlm.nih.gov/pubmed/17710205. \n681. Patchell RA, Tibbs PA, Walsh JW, et al. A randomized trial of surgery \nin the treatment of single metastases to the brain. N Engl J Med \n1990;322:494-500. Available at: \nhttps://www.ncbi.nlm.nih.gov/pubmed/2405271. \n682. Linskey ME, Andrews DW, Asher AL, et al. The role of stereotactic \nradiosurgery in the management of patients with newly diagnosed brain \nmetastases: a systematic review and evidence-based clinical practice \nguideline. J Neurooncol 2010;96:45-68. Available at: \nhttps://www.ncbi.nlm.nih.gov/pubmed/19960227. \n683. Aoyama H, Shirato H, Tago M, et al. Stereotactic radiosurgery plus \nwhole-brain radiation therapy vs stereotactic radiosurgery alone for \ntreatment of brain metastases: a randomized controlled trial. JAMA', 'Neurooncol 2010;96:71-83. Available at: \nhttps://www.ncbi.nlm.nih.gov/pubmed/19960229. \n686. Ellis TL, Neal MT, Chan MD. The role of surgery, radiosurgery and \nwhole brain radiation therapy in the management of patients with \nmetastatic brain tumors. Int J Surg Oncol 2012;2012:952345. Available at: \nhttps://www.ncbi.nlm.nih.gov/pubmed/22312545. \n687. Patchell RA, Tibbs PA, Regine WF, et al. Postoperative radiotherapy \nin the treatment of single metastases to the brain: a randomized trial. \nJAMA 1998;280:1485-1489. Available at: \nhttps://www.ncbi.nlm.nih.gov/pubmed/9809728. \n688. Ammirati M, Cobbs CS, Linskey ME, et al. The role of retreatment in \nthe management of recurrent/progressive brain metastases: a systematic \nreview and evidence-based clinical practice guideline. J Neurooncol \n2010;96:85-96. Available at: \nhttps://www.ncbi.nlm.nih.gov/pubmed/19957016. \n689. Bradbury P, Sivajohanathan D, Chan A, et al. Postoperative Adjuvant', 'Disease Control in Patients Undergoing Stereotactic Radiosurgery and \nImmune Checkpoint Inhibitor Therapy for Brain Metastases. World \nNeurosurg 2019;126:e1399-e1411. Available at: \nhttps://www.ncbi.nlm.nih.gov/pubmed/30902777. \n678. Kalkanis SN, Kondziolka D, Gaspar LE, et al. The role of surgical \nresection in the management of newly diagnosed brain metastases: a \nsystematic review and evidence-based clinical practice guideline. J \nNeurooncol 2010;96:33-43. Available at: \nhttps://www.ncbi.nlm.nih.gov/pubmed/19960230. \n679. Gaspar LE, Mehta MP, Patchell RA, et al. The role of whole brain \nradiation therapy in the management of newly diagnosed brain \nmetastases: a systematic review and evidence-based clinical practice \nguideline. J Neurooncol 2010;96:17-32. Available at: \nhttps://www.ncbi.nlm.nih.gov/pubmed/19960231. \n680. Mintz A, Perry J, Spithoff K, et al. Management of single brain \nmetastasis: a practice guideline. Curr Oncol 2007;14:131-143. Available', 'Trial. JAMA 2016;316:401-409. Available at: \nhttps://www.ncbi.nlm.nih.gov/pubmed/27458945. \n237. Yamamoto M, Serizawa T, Shuto T, et al. Stereotactic radiosurgery \nfor patients with multiple brain metastases (JLGK0901): a multi-\ninstitutional prospective observational study. Lancet Oncol 2014;15:387-\n395. Available at: https://www.ncbi.nlm.nih.gov/pubmed/24621620. \n238. Reck M, Popat S, Reinmuth N, et al. Metastatic non-small-cell lung \ncancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, \ntreatment and follow-up. Ann Oncol 2014;25 Suppl 3:iii27-39. Available at: \nhttps://www.ncbi.nlm.nih.gov/pubmed/25115305. \n239. Tsao MN, Lloyd N, Wong RK, et al. Whole brain radiotherapy for the \ntreatment of newly diagnosed multiple brain metastases. Cochrane \nDatabase Syst Rev 2012;4:CD003869. Available at: \nhttps://www.ncbi.nlm.nih.gov/pubmed/22513917. \n240. Chang WS, Kim HY, Chang JW, et al. Analysis of radiosurgical']","The title of the randomized trial conducted by Patchell RA and colleagues regarding the treatment of single metastases to the brain is ""A randomized trial of surgery in the treatment of single metastases to the brain"" (NCCN_Breast_2024.pdf, p.262).","https://www.ncbi.nlm.nih.gov/pubmed/19960231. 
680. Mintz A, Perry J, Spithoff K, et al. Management of single brain 
metastasis: a practice guideline. Curr Oncol 2007;14:131-143. Available 
at: https://www.ncbi.nlm.nih.gov/pubmed/17710205. 
681. Patchell RA, Tibbs PA, Walsh JW, et al. A randomized trial of surgery 
in the treatment of single metastases to the brain. N Engl J Med 
1990;322:494-500. Available at: 
https://www.ncbi.nlm.nih.gov/pubmed/2405271. 
682. Linskey ME, Andrews DW, Asher AL, et al. The role of stereotactic 
radiosurgery in the management of patients with newly diagnosed brain 
metastases: a systematic review and evidence-based clinical practice 
guideline. J Neurooncol 2010;96:45-68. Available at: 
https://www.ncbi.nlm.nih.gov/pubmed/19960227. 
683. Aoyama H, Shirato H, Tago M, et al. Stereotactic radiosurgery plus 
whole-brain radiation therapy vs stereotactic radiosurgery alone for 
treatment of brain metastases: a randomized controlled trial. JAMA",0.5,1.0000000000000002,0.999999999975
What is the recommended first-line therapy option for eligible patients with metastatic NSCLC and PD-L1 expression levels of 1% to 49% according to the NCCN NSCLC Panel?,"['with initial cytotoxic systemic therapy regimens (eg, carboplatin plus \npaclitaxel) is recommended by the NCCN NSCLC Panel.  \nThe NCCN NSCLC Panel also recommends single-agent pembrolizumab \nas a first-line therapy option (category 2B; useful in certain \ncircumstances) for eligible patients with metastatic NSCLC, PD-L1 \nexpression levels of 1% to 49%, no contraindications to PD-1 or PD-L1 \ninhibitors, and negative test results for actionable driver mutations based \non clinical trial data and FDA approval.832,869 The NCCN NSCLC Panel \ndecided that single-agent pembrolizumab is a useful intervention in \npatients with PD-L1 levels of 1% to 49% when there are contradictions to \ncombination chemotherapy (category 2B; useful in certain \ncircumstances). In patients with PD-L1 levels of 1% to 49%, the HR of \n0.92 is not statistically or clinically significant for pembrolizumab \nmonotherapy versus chemotherapy; therefore, pembrolizumab plus', 'Chemoradiation in this Discussion).363  \nSingle-agent pembrolizumab, atezolizumab, or cemiplimab-rwlc are \nrecommended (category 1; preferred) as first-line therapy options for \neligible patients with metastatic NSCLC regardless of histology, PD-L1 \nexpression levels of 50% or more, and negative test results for actionable \ndriver mutations that have recommended first-line targeted therapies (ie, \nALK, BRAF p.V600E, EGFR, METex14 skipping, NTRK1/2/3, RET, \nROS1). The NCCN NSCLC Panel recommends single-agent \npembrolizumab as a first-line therapy option in eligible patients with \nmetastatic NSCLC regardless of histology, PD-L1 levels of 1% to 49% \n(category 2B; useful in certain circumstances), and negative test results \nfor actionable driver mutations.832  \nCombination therapy with pembrolizumab plus chemotherapy is \nrecommended (category 1; preferred) as a first-line therapy option in \neligible patients with metastatic NSCLC and negative test results for', 'and either carboplatin or cisplatin (category 1; preferred) as a first-line \ntherapy option for eligible patients with metastatic nonsquamous NSCLC \n(ie, adenocarcinoma, large cell carcinoma) or NSCLC NOS based on \nclinical trial data and FDA approval.711,712 The NCCN NSCLC Panel has \npreference stratified the systemic therapy regimens and decided that \nthese pembrolizumab plus chemotherapy regimens are preferred first-line \noptions for eligible patients with metastatic nonsquamous NSCLC. These \npembrolizumab plus chemotherapy regimens are recommended (category \n1; preferred) as first-line therapy options for patients with metastatic \nnonsquamous NSCLC, no contraindications to PD-1 or PD-L1 inhibitors, \nand negative test results for actionable driver mutations, regardless of \ntheir PD-L1 expression levels. Maintenance therapy with pembrolizumab \nplus pemetrexed is also a recommended option (category 1) in this setting.', 'shown in the algorithm. Targeted therapy is a preferred first-line therapy \noption for patients with actionable driver mutations, except for EGFR exon \n20 mutations or KRAS mutations.  \nThe NCCN NSCLC Panel has preference stratified the systemic therapy \nregimens and decided that first-line therapy with nivolumab plus \nipilimumab is “useful in certain circumstances” (eg, renal impairment) for \npatients with PD-L1 levels of 50% or more and is an “other recommended” \nfirst-line therapy option for patients with PD-L1 levels less than 50%. For \nthe 2023 update (Version 1), the NCCN Panel revised the preference \nstratification for first-line therapy with nivolumab plus ipilimumab to an \n“other recommended” option from useful in certain circumstances in \npatients with PD-L1 levels of 1% to 49%. Previously, the NCCN Panel \ndeleted TMB as an emerging immune biomarker based on clinical trial \ndata and other issues (see TMB in this Discussion).171 The NCCN']","The recommended first-line therapy option for eligible patients with metastatic NSCLC and PD-L1 expression levels of 1% to 49% according to the NCCN NSCLC Panel is single-agent pembrolizumab (category 2B; useful in certain circumstances) when there are no contraindications to PD-1 or PD-L1 inhibitors and negative test results for actionable driver mutations (nscl.pdf, p.180).","with initial cytotoxic systemic therapy regimens (eg, carboplatin plus 
paclitaxel) is recommended by the NCCN NSCLC Panel.  
The NCCN NSCLC Panel also recommends single-agent pembrolizumab 
as a first-line therapy option (category 2B; useful in certain 
circumstances) for eligible patients with metastatic NSCLC, PD-L1 
expression levels of 1% to 49%, no contraindications to PD-1 or PD-L1 
inhibitors, and negative test results for actionable driver mutations based 
on clinical trial data and FDA approval.832,869 The NCCN NSCLC Panel 
decided that single-agent pembrolizumab is a useful intervention in 
patients with PD-L1 levels of 1% to 49% when there are contradictions to 
combination chemotherapy (category 2B; useful in certain 
circumstances). In patients with PD-L1 levels of 1% to 49%, the HR of 
0.92 is not statistically or clinically significant for pembrolizumab 
monotherapy versus chemotherapy; therefore, pembrolizumab plus",1.0,0.9801133582940881,0.999999999975
What are the recommended first-line therapy options for patients with metastatic squamous cell NSCLC who have negative test results for actionable driver mutations?,"['Advanced or Metastatic Disease in the NCCN Guidelines for NSCLC). \nFirst-line targeted therapy options are recommended for eligible patients \nwith metastatic NSCLC and positive test results for actionable driver \nmutations such as ALK, BRAF p.V600E, EGFR, METex14 skipping, \nNTRK1/2/3, RET, and ROS1. Second-line targeted therapy options are \nrecommended for eligible patients with metastatic NSCLC and positive \ntest results for EGFR exon 20 insertions or KRAS p.G12C mutations. \nFirst-line immunotherapy options are recommended for eligible patients \nwith metastatic NSCLC and negative test results for actionable driver \nmutations. Immunotherapy options may be used as first-line or \nsubsequent therapy options in eligible patients with actionable driver \nmutations as shown in the algorithm, although they are generally not \npreferred options.  \nStage I, Stage II, and Stage IIIA Disease \nDepending on the extent and type of comorbidity present, patients with', 'For patients with metastatic squamous cell NSCLC and negative test \nresults for actionable driver mutations, chemotherapy plus \nimmunotherapy regimens—such as pembrolizumab plus carboplatin with \neither paclitaxel or albumin-bound paclitaxel—are recommended options \n(category 1; preferred). For patients with metastatic squamous cell NSCLC \nwho have contraindications to ICIs, recommended options include cisplatin \nplus gemcitabine (category 1).790 Carboplatin plus paclitaxel, carboplatin \nplus gemcitabine (category 1 for both), and other regimens listed in the \nNSCLC algorithm are also recommended options (see Systemic Therapy \nfor Advanced or Metastatic Disease in the NCCN Guidelines for NSCLC, \nthe NCCN Compendium® for NSCLC, and the NCCN Guidelines with \nEvidence Blocks™ for NSCLC). Data supporting the combination \nplatinum-based chemotherapy options are described in the following \nsections (see Clinical Trial Data in this Discussion). These chemotherapy', 'squamous cell NSCLC. These pembrolizumab plus chemotherapy \nregimens are recommended (category 1; preferred) as first-line therapy \noptions for patients with metastatic squamous cell NSCLC, no \ncontraindications to PD-1 or PD-L1 inhibitors, and negative test results for \nactionable driver mutations, regardless of their PD-L1 expression levels. \nThe panel does not recommend pembrolizumab plus cisplatin with either \npaclitaxel or albumin-bound paclitaxel, because there are fewer data for \nthis regimen. Combination therapy with pembrolizumab plus carboplatin \nand either paclitaxel or albumin-bound paclitaxel may be used as a \nfirst-line or subsequent therapy option in eligible patients with actionable \ndriver mutations as shown in the algorithm. However, targeted therapy is \na preferred first-line therapy option for patients with actionable driver \nmutations, except for EGFR exon 20 mutations or KRAS mutations. \nSubsequent Therapy', 'data and FDA approval.855,857 For metastatic nonsquamous NSCLC, the \nrecommended chemotherapy is pemetrexed with either cisplatin or \ncarboplatin; for metastatic squamous NSCLC, the recommended \nchemotherapy is paclitaxel with carboplatin. Nivolumab plus ipilimumab \nplus chemotherapy is recommended for patients with metastatic NSCLC, \nregardless of PD-L1 levels; negative test results for actionable driver \nmutations; and no contraindications to PD-1/PD-L1 inhibitors. \nMaintenance therapy with nivolumab plus ipilimumab is also \nrecommended. Combination therapy with nivolumab plus ipilimumab may \nbe used as a first-line or subsequent therapy option, although it is not a \npreferred option, in eligible patients with actionable driver mutations as \nshown in the algorithm. Targeted therapy is a preferred first-line therapy \noption for patients with actionable driver mutations, except for EGFR exon \n20 mutations or KRAS mutations. The panel has preference stratified the']","The recommended first-line therapy options for patients with metastatic squamous cell NSCLC who have negative test results for actionable driver mutations include chemotherapy plus immunotherapy regimens, such as pembrolizumab plus carboplatin with either paclitaxel or albumin-bound paclitaxel (NCCN_Breast_2024.pdf, p.217). Additionally, the panel recommends pembrolizumab plus chemotherapy regimens as preferred options, regardless of PD-L1 expression levels (NCCN_Breast_2024.pdf, p.181).","squamous cell NSCLC. These pembrolizumab plus chemotherapy 
regimens are recommended (category 1; preferred) as first-line therapy 
options for patients with metastatic squamous cell NSCLC, no 
contraindications to PD-1 or PD-L1 inhibitors, and negative test results for 
actionable driver mutations, regardless of their PD-L1 expression levels. 
The panel does not recommend pembrolizumab plus cisplatin with either 
paclitaxel or albumin-bound paclitaxel, because there are fewer data for 
this regimen. Combination therapy with pembrolizumab plus carboplatin 
and either paclitaxel or albumin-bound paclitaxel may be used as a 
first-line or subsequent therapy option in eligible patients with actionable 
driver mutations as shown in the algorithm. However, targeted therapy is 
a preferred first-line therapy option for patients with actionable driver 
mutations, except for EGFR exon 20 mutations or KRAS mutations. 
Subsequent Therapy",1.0,1.0000000000000002,0.999999999975
What may necessitate an increase in the proportional enrollment of a certain population in a clinical study?,"['differential pharmacokinetics (PK), pharmacodynamics (PD), or due to possible differences in \n196 \nsusceptibility to specific adverse events of concern for a drug or medical device), or due to \n197 \ndifferential presentation of the disease or condition. In some cases, it may be necessary to \n198 \nincrease the proportional enrollment of a certain population in the clinical study to evaluate \n199 \noutcomes of interest or other clinically relevant factors in that group.  \n200 \n \n201 \n \n37 See 83 FR 7366, Human Subject Protection: Acceptance of Data From Clinical Investigations for Medical \nDevices. \n38 Sections 505(z)(2) and 520(g)(9)(B) of the FD&C Act; see also section 3602 of FDORA.', '352 \nacross the clinically relevant population such as possible differences in PK or \n353 \npharmacodynamics (PD). Sponsors should also describe available data regarding \n354 \ndifferences in PK, PD, safety, or effectiveness (e.g., by sex, age, or by genetic \n355 \nvariations which may be more prevalent in certain racial and ethnic populations \n356 \nthat impact drug metabolism or susceptibility to adverse reactions)55 in the \n357 \nDiversity Action Plan. Additionally, sponsors should describe, as applicable, the \n358 \nrelevancy of other population-level or individual characteristics that available \n359 \ndata suggest have an impact on the clinical outcomes (e.g., SES, geographic \n360 \nlocation, comorbidities). Sponsors should include citations for the sources of data \n361 \nand information (e.g., epidemiological databases, registries, etc.) upon which \n362 \nrationales for enrollment goals are based.   \n363 \no For devices, the rationale for enrollment goals should describe data and \n364', '299 \nforeign clinical sites and defining geographic regions. A Diversity Action Plan for a multi-\n300 \nnational clinical study must describe participant enrollment goals for the entire study45 and \n301 \nshould not be limited to U.S.-enrolled participants. Additionally, the overall study design, \n302 \nincluding the selection of study sites, should account for the need to enroll a population \n303 \nrepresentative of the U.S. intended use population as part of the overall medical product \n304 \ndevelopment program. FDA recognizes that the lack of uniformity across the globe in the use of \n305 \npopulation descriptors such as race and ethnicity may pose challenges when setting enrollment \n306 \ngoals for international sites. For example, it may be challenging to identify corresponding \n307 \npopulations defined on the basis of race or ethnicity when describing the affected population \n308 \noutside the U.S. and consequently, when setting enrollment goals for the clinical study. Sponsors \n309', '248 \nDiversity Action Plan for each clinical study should reflect a strategy that leads to an overall \n249 \nproportionate representation, even though individual clinical studies may not have proportionate \n250 \nrepresentation.  \n251 \nFDA recognizes that certain development programs (e.g., rare diseases), may include a single, \n252 \nsmall pivotal study. Despite enrolling a representative population in that study, participant \n253 \nnumbers may be small, potentially precluding the detection of any differences in safety and \n254 \neffectiveness across the study population, should they exist, or limiting the sponsor’s ability to \n255 \nconduct a robust assessment of observed differences. However, consistent representative \n256 \nenrollment may provide opportunities for hypothesis generation and further study.  \n257 \nWhenever possible, sponsors should utilize appropriate available sources (e.g., certain registries \n258']","An increase in the proportional enrollment of a certain population in a clinical study may be necessary to evaluate outcomes of interest or other clinically relevant factors in that group, particularly due to differential pharmacokinetics (PK), pharmacodynamics (PD), or possible differences in susceptibility to specific adverse events of concern for a drug or medical device (FDA-2021-D-0789-0111_attachment_1.pdf, p.10).","differential pharmacokinetics (PK), pharmacodynamics (PD), or due to possible differences in 
196 
susceptibility to specific adverse events of concern for a drug or medical device), or due to 
197 
differential presentation of the disease or condition. In some cases, it may be necessary to 
198 
increase the proportional enrollment of a certain population in the clinical study to evaluate 
199 
outcomes of interest or other clinically relevant factors in that group.  
200 
 
201 
 
37 See 83 FR 7366, Human Subject Protection: Acceptance of Data From Clinical Investigations for Medical 
Devices. 
38 Sections 505(z)(2) and 520(g)(9)(B) of the FD&C Act; see also section 3602 of FDORA.",1.0,0.0,0.999999999975
What type of patients were included in the PACIFIC trial mentioned in the text?,"['may be used as a consolidation immunotherapy option after treatment with \nany of the concurrent chemoradiation regimens described in the algorithm \n(eg, cisplatin plus etoposide, carboplatin plus paclitaxel) (see Concurrent \nChemoradiation Regimens in the NCCN Guidelines for NSCLC). Ten \npatients with stage II NSCLC were included in the PACIFIC trial, which \nused the older AJCC staging criteria (7th edition). Therefore, the NCCN \nPLEASE NOTE that use of this NCCN Content is governed by the End-User License Agreement, and you MAY NOT distribute this Content or use it with any artificial intelligence model or tool.\nPrinted by Robin Ede on 11/23/2025 3:16:18 PM. Copyright © 2025 National Comprehensive Cancer Network, Inc. All Rights Reserved.', 'TABLE 2.\u2002 Characteristics of the Study Population\nCharacteristics\nNo. of Study Participants\nTotal  \nN\xa0=\xa091\nPrincipal Investigator \nN\xa0=\xa034\nResearch Staff \nN\xa0=\xa033\nReferring Clinician \nN\xa0=\xa016\nCancer Center \nLeadership N\xa0=\xa08\nMean age, y\n51\n46\n52\n48\n60\nSex, no.\n\xa0\n\xa0\n\xa0\n\xa0\n\xa0\nMen\n43\n21\n3\n12\n7\nWomen\n48\n13\n30\n4\n1\nRace, no.\n\xa0\n\xa0\n\xa0\n\xa0\n\xa0\nWhite\n67\n24\n26\n10\n7\nAfrican American\n11\n3\n5\n3\n0\nAsian\n13\n7\n2\n3\n1\nEthnicity, no.\n\xa0\n\xa0\n\xa0\n\xa0\n\xa0\nNon-Hispanic\n76\n29\n30\n11\n6\nHispanic\n15\n5\n3\n5\n2\nMean no. of y of cancer trial experience\n12\n11\n10\n13\n24\nType of trial, no.\n\xa0\n\xa0\n\xa0\n\xa0\n\xa0\nTherapeutic\n27\n4\n19\n2\n2\nNontherapeutic\n6\n5\n1\n0\n0\nTherapeutic and nontherapeutic\n56\n24\n12\n14\n6\nNot indicated\n2\n1\n1\n0\n0\n 10970142, 2020, 9, Downloaded from https://acsjournals.onlinelibrary.wiley.com/doi/10.1002/cncr.32755, Wiley Online Library on [23/11/2025]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License', 'Clin Pharmacol Ther 2018;103:631-642.\n8 Spigel DR, Faivre-Finn C, Gray JE, et al. Five-year survival outcomes from the PACIFIC Trial: Durvalumab after chemoradiotherapy in stage III non-small-cell lung \ncancer. J Clin Oncol 2022;40:1301-1311.\n9 Lu S, Kato T, Dong X, et al. Osimertinib after chemoradiotherapy in stage III EGFR-mutated NSCLC. N Engl J Med 2024;391:585-597.\nPLEASE NOTE that use of this NCCN Content is governed by the End-User License Agreement, and you MAY NOT distribute this Content or use it with any artificial intelligence model or tool.\nPrinted by Robin Ede on 11/23/2025 3:16:18 PM. Copyright © 2025 National Comprehensive Cancer Network, Inc. All Rights Reserved.', 'in particular were examined to ensure that further revi-\nsions to the data collection and analytic processes were \nnot needed.\nStudy Population\nQualitative interviews were conducted at each site among \n4 key stakeholder groups: 1) principal investigators; 2) \nresearch staff; 3) referring clinicians; and 4) cancer center \nleaders. Investigators used administrative data regarding \nexisting oncology studies and personal contacts to iden-\ntify eligible participants. Participants in each stakeholder \ngroup were recruited based on group-specific eligibility \ncriteria (Table 1).\n 10970142, 2020, 9, Downloaded from https://acsjournals.onlinelibrary.wiley.com/doi/10.1002/cncr.32755, Wiley Online Library on [23/11/2025]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License']","The PACIFIC trial included patients with stage III non-small-cell lung cancer (NSCLC) (nscl.pdf, p.165).","may be used as a consolidation immunotherapy option after treatment with 
any of the concurrent chemoradiation regimens described in the algorithm 
(eg, cisplatin plus etoposide, carboplatin plus paclitaxel) (see Concurrent 
Chemoradiation Regimens in the NCCN Guidelines for NSCLC). Ten 
patients with stage II NSCLC were included in the PACIFIC trial, which 
used the older AJCC staging criteria (7th edition). Therefore, the NCCN 
PLEASE NOTE that use of this NCCN Content is governed by the End-User License Agreement, and you MAY NOT distribute this Content or use it with any artificial intelligence model or tool.
Printed by Robin Ede on 11/23/2025 3:16:18 PM. Copyright © 2025 National Comprehensive Cancer Network, Inc. All Rights Reserved.",0.6666666666666666,0.9643159054879338,0.9999999999
